Patients with chronic kidney disease (CKD) display a strong association with atherosclerotic cardiovascular disease (ASCVD) as compared with the general population.^1-3 To date, there are no ASCVD risk prediction models to identify optimal treatments and prevention therapies for this high-risk population of CKD.¹ A recent study published by Bundy and colleagues in the Journal of the American Society of Nephrology, developed and validated 10-year ASCVD risk prediction models among CKD patients, which included novel kidney and cardiac biomarkers to improve the prediction performance and clinical outcomes.¹

Patients with chronic kidney disease (CKD) display a strong association with atherosclerotic cardiovascular disease (ASCVD) as compared with the general population.^1-3 To date, there are no ASCVD risk prediction models to identify optimal treatments and prevention therapies for this high-risk population of CKD.¹ A recent study published by Bundy and colleagues in the Journal of the American Society of Nephrology, developed and validated 10-year ASCVD risk prediction models among CKD patients, which included novel kidney and cardiac biomarkers to improve the prediction performance and clinical outcomes.¹

A recent randomized, phase 2 study by Gane, E.J. and colleagues presented at the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2021 demonstrated the high long-term efficacy and safety of tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF) antiviral prophylaxis in post-orthotopic liver transplant (OLT) patients with chronic hepatitis B virus (HBV) infection.¹ The renal- and bone-protecting effects on patients with TAF were shown to be more profound than those with TDF.¹

Heart failure (HF) is highly prevalent in patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) and is strongly associated with mortality in these patients.1 HF in ESKD is defined based on patient-reported dyspnea assessed both pre- and post-ultrafiltration, in conjunction w

Asthma is a chronic inflammatory disease of the airways that affects approximately 300 million people globally with about 5-10% of asthmatics being severe asthma.¹ Severe asthma typically requires treatment with high-dose inhaled corticosteroid (ICS) plus a second controller and/or systemic corticos